Experimental CAR T-Cell therapy targets tough leukemias
NCT ID NCT07471789
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing an experimental treatment called CART84 for people with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack leukemia cells. The study aims to find a safe dose and look for early signs that CART84 may help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CART84 (GYA01), a CAR T-cell therapy made from the patient's own immune cells
What this could lead to
If it works, this could offer a new treatment option for people with hard-to-treat leukemias that have not responded to standard therapies.
What could go wrong
This is an early, small trial (33 people) focused on safety and dosing. The therapy may cause severe side effects or fail to control the leukemia. Success is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Hospital Clínic de Barcelona
RECRUITINGBarcelona, Barcelona, 08036, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario y Politécnico La Fe
RECRUITINGValencia, Valencia, 46026, Spain
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••